NIFTYMID150 Archives - ChartAlert®

SYNGENE – Syngene International – Q4 FY26 Financial Results – 29-Apr-26

Syngene’s FY26 saw 2.6% revenue growth and 36% profit fall, with 400–500 bps margin hit from forex/employee costs. Strong FCF and near‑zero debt provide balance sheet comfort. Q4 recovery hints charges easing, but sustained EBITDA >28% hinges on cost discipline and hedging restructure.

1–2 minutes

🔍 Observations

Topline

FY26 revenue grew 2.6% YoY (₹36,424M → ₹37,387M) — modest, indicating demand stabilisation rather than acceleration; Q4FY26 added ₹10,365M vs ₹10,180M in Q4FY25, a 1.8% quarterly comp.
Sequential Q4 bounce of 13% (₹9,171M → ₹10,365M) signals some seasonality recovery after a soft Q3.
Revenue growth materially trails cost growth — total expenses rose 7.6% YoY vs revenue’s 2.6%, squeezing every margin line.

Bottomline

FY26 PAT collapsed 36.2% YoY (₹4,962M → ₹3,167M), driven by cost inflation, a ₹766M net exceptional loss, and a ₹590M forex drag vs near-neutral ₹19M in FY25.
Excluding exceptionals, PBT fell 22.4% (₹6,279M → ₹4,875M) — underlying operations deteriorated significantly, not just optics.
Q4FY26 PAT at ₹1,479M vs ₹1,833M in Q4FY25 (-19.3%) confirms the weakness persists into year-end.

Margins

EBITDA proxy (PBT before exceptionals + D&A + Finance costs): FY26 = ₹4,875 + ₹4,529 + ₹488 = ₹9,892M; FY25 = ₹6,279 + ₹4,326 + ₹531 = ₹11,136M. EBITDA margin: FY26 = 26.5% vs FY25 = 30.6% — a 410 bps contraction.
Net profit margin: FY26 = 8.5% (₹3,167M ÷ ₹37,387M) vs FY25 = 13.6% (₹4,962M ÷ ₹36,424M) — 510 bps erosion.
Employee costs surged 12.3% YoY (₹9,839M → ₹11,049M), now representing 29.6% of revenue vs 27.0% in FY25 — the single largest margin headwind.

Growth Trajectory

Two-year revenue trajectory is nearly flat: FY25 grew off a likely stronger FY24 base; FY26 adds only ₹963M incremental — structural growth slowdown is apparent.
EPS declined 36.3% YoY (₹12.35 → ₹7.87), compressing shareholder returns sharply and raising questions about near-term re-rating potential.
Capex is decelerating — PP&E purchases dropped from ₹7,603M (FY25) to ₹3,440M (FY26), suggesting the investment cycle is maturing; growth acceleration from new capacity depends on utilisation ramp.

APARINDS – Q3 FY26 Earnings Call – 29-Jan-26

APARINDS’ topline likely tracks 20%+ CAGR on domestic resilience (renewables, railways, data centers) and U.S. order rebound, but margins face 100–150 bps compression from tariffs/commodities; bottomline hinges on capex utilization timing and transmission catch-up in H2 FY26.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: U.S. tariffs ease in H2 FY27; transmission additions catch up in Q4 (government concessions); commodity prices stabilize.
Outcome: Cable revenue grows 20–22% (INR 500 crore U.S. orders executed); conductor volumes at 8–9%. EBITDA margins hold at 9.5–10%. Capex utilization ramps in FY28; ROIC 12–14%. EPS grows 15–18% YoY, tracking guidance.

SYNGENE – Q3 FY26 Earnings Call – 23-Jan-26

SYNGENE’s topline faces near-term headwinds from single-product concentration, but diversification efforts (BMS, Bayview, clinical trials) could stabilize revenue by FY27; margins hinge on CDMO utilization and cost discipline, with EBITDA recovery lagging revenue by 12–18 months. Cash flow remains resilient but vulnerable to CAPEX overruns or prolonged revenue drag.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Librela stabilizes by H2 FY27, with partial revenue recovery (50% of lost run-rate). CDMO utilization reaches 60–70% in Mangalore/Bayview, driven by 1–2 new large-molecule contracts. Research services grow 8–10%, supported by biotech funding. FY27 revenue flat to +2%, EBITDA margins 23–25%.
Trigger: Zoetis resolves product issues; Syngene secures $20–30M annual CDMO contracts.